JPM vs JRS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
JRS presents a complex profile with a stable Piotroski F-Score of 4/9, but significant fundamental contradictions. While the fund trades almost exactly at its book value (P/B 0.99) and shows strong revenue growth of 28.1%, it is suffering from a severe earnings collapse of -75.7%. The most critical concern is the unsustainable dividend payout ratio of 133.33%, indicating that distributions are not being covered by current earnings. Despite recent short-term price momentum, the underlying profitability and liquidity metrics remain weak.
Compare Another Pair
Related Comparisons
JPM vs JRS: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen Real Estate Income Fund (JRS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.